Extended Data Fig. 6: Characterization of murine TFR cells in an immunization and cancer setting.
From: Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy
a, Gating strategy to identify tumor-infiltrating TREG (CD19–CD45+CD3+CD4+BCL-6–FOXP3+) and TFR (CD19–CD45+CD3+CD4+BCL-6+FOXP3+) cells in B16F10-OVA inoculated mice at d21 (upper panel), shown are representative FACS plots. The FACS plots in the lower panel illustrate intracellular expression of BCL-6 in the indicated cell types (left panel), expression of GITR (middle upper panel), KI-67 (right upper panel), PD-1 (middle lower panel), and CTLA-4 (right lower panel) versus FOXP3 in CD4+ T cells. b, Contour plots depicting the expression levels of FOXP3 in the indicated cell populations from (Fig. 4d). c, Luminex analysis of supernatants from an in vitro proliferation assay (repeat of in vitro suppression assay experiment in Fig. 4g,h), depicted is the concentration of secreted IFN-γ, IL-2 and TNF. d, Flow-cytometric analysis of the frequency of tumor-infiltrating TREG and TFR cells (P = 0.0025 in MC38-OVA, n = 5 mice for day 14 and n = 7 mice for day 21; P = 0.0017 in B16F10-OVA, n = 10 mice for day 14 and n = 6 mice for day 21) in indicated tumor models at indicated time points. Data are mean + /− s.e.m., Significance for comparisons were computed using two-tailed Mann–Whitney test (d). Data in b-d are representative of two independent experiments.
